Vivanza Biosciences Limited (BOM:530057)

Vivanza Biosciences Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	0.65	1.17	1.67	1.41	0.55
Short-Term Investments	-	0.3	0.29	0.29	0.01
Cash & Short-Term Investments	0.65	1.47	1.96	1.7	0.56
Cash Growth	-55.52%	-25.03%	15.11%	203.21%	-
Accounts Receivable	123.83	80.59	115.39	124.79	78.4
Receivables	150.93	97.03	131.62	166.11	97.69
Inventory	35.51	22.63	20.06	24.75	24.28
Other Current Assets	3.46	2.72	3.77	2.98	1.98
Total Current Assets	190.55	123.84	157.41	195.54	124.51
Property, Plant & Equipment	8.01	6.99	7.05	6.8	6.82
Long-Term Investments	0.03	0.03	0.03	0.03	0.03
Goodwill	-	16.05	16.05	16.05	16.05
Other Intangible Assets	16.35	0.3	0.3	0.3	0.3
Long-Term Deferred Tax Assets	-	0.01	0.02	0.01	0.01
Other Long-Term Assets	5.93	5.93	5.93	5.93	5.93
Total Assets	220.87	164.53	195.01	224.77	155.62

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	71.94	26.18	82.35	95.49	54.85
Accrued Expenses	1.61	0.37	0.22	0.25	0.22
Short-Term Debt	-	18.74	22.07	32.77	27.36
Current Portion of Long-Term Debt	93.15	34.44	2.81	32.87	1.75
Current Income Taxes Payable	-	0.23	2.67	1.43	0.25
Current Unearned Revenue	-	5.42	4.19	6.6	3.98
Other Current Liabilities	1.82	6.17	7.52	0.13	6.32
Total Current Liabilities	168.52	91.54	121.81	169.53	94.73
Long-Term Debt	8.77	33.35	26.82	14.33	25.97
Long-Term Deferred Tax Liabilities	0	-	-	-	-
Other Long-Term Liabilities	-	0	0	-	-
Total Liabilities	177.29	124.89	148.63	183.86	120.69

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	40	40	40	40	40
Retained Earnings	3.59	-0.36	6.38	0.91	-5.08
Shareholders' Equity	43.59	39.64	46.38	40.91	34.93
Total Liabilities & Equity	220.87	164.53	195.01	224.77	155.62

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	101.92	86.52	51.7	79.97	55.08
Net Cash (Debt)	-101.27	-85.05	-49.74	-78.27	-54.52
Net Cash Growth	-	-	-	-	-
Net Cash Per Share	-2.57	-2.13	-1.27	-1.96	-1.36
Filing Date Shares Outstanding	40.98	40	40	40	40
Total Common Shares Outstanding	40.98	40	40	40	40
Working Capital	22.03	32.3	35.6	26.01	29.78
Book Value Per Share	1.06	0.99	1.16	1.02	0.87
Tangible Book Value	27.23	23.29	30.03	24.56	18.57
Tangible Book Value Per Share	0.66	0.58	0.75	0.61	0.46
Land	-	1.42	1.42	1.42	1.42
Buildings	-	2.46	2.46	2.46	2.46
Machinery	-	5.37	5.29	4.92	4.92

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 24, 2026

Data Sources Report a data error